Das K M, Eastwood M A
Clin Pharmacol Ther. 1975 Nov;18(5 Pt 1):514-20. doi: 10.1002/cpt1975185part1514.
Sulfapyridine (SP) is one of the main metabolites of salicylazosulfapyridine (sulfasalazine) that is used extensively in the management of inflammatory bowel disease. One hundred and twenty-two patients with ulcerative colitis or Crohn's disease were studied, including 21 new, untreated patients and 101 previously treated patients. Patients were studied for at least one year during active disease and remission. It was shown that sulfapyridine shares the same acetylation polymorphism as sulfadimidine. The acetylation capability of each patient as determined in serum and urine was constant irrespective of dose (2 to 8 gm/day) and state of disease. A single study of serum can determine acetylator phenotype in patients on sulfasalazine therapy without using any other drug for this purpose and may help ascertain dosage and assess side effects.
磺胺吡啶（SP）是柳氮磺胺吡啶（柳氮磺吡啶）的主要代谢产物之一，在炎症性肠病的治疗中广泛应用。对122例溃疡性结肠炎或克罗恩病患者进行了研究，其中包括21例未经治疗的新发病例和101例既往接受过治疗的病例。在疾病活动期和缓解期对患者进行了至少一年的研究。结果表明，磺胺吡啶与磺胺二甲嘧啶具有相同的乙酰化多态性。无论剂量（2至8克/天）和疾病状态如何，通过血清和尿液测定的每位患者的乙酰化能力都是恒定的。单次血清研究即可确定接受柳氮磺胺吡啶治疗患者的乙酰化表型，无需为此使用任何其他药物，这可能有助于确定剂量并评估副作用。
